603038-76-2Relevant academic research and scientific papers
Discovery of an in vitro and in vivo potent resorcylic lactone analog of LL-Z1640-2 as anti-inflammatory lead, II
Shen, Yongchun,Du, Hong,Kotake, Makoto,Matsushima, Tomohiro,Goto, Masaki,Shirota, Hiroshi,Gusovsky, Fabian,Li, Xiangyi,Jiang, Yimin,Schiller, Shawn,Spyvee, Mark,Davis, Heather,Zhang, Zhiyi,Pelletier, Robert,Ikemori-Kawada, Megumi,Kawakami, Yoshiyuki,Inoue, Atsushi,Wang, Yuan
scheme or table, p. 3047 - 3049 (2010/07/18)
The potent in vitro lead compound, ER-803064 (2), a MEK1 and MEKK1 inhibitor inspired from natural product LL-Z1640-2 (f152A1), was further optimized to improve in vitro and in vivo potency. The modifications on C14 position led to discovery of the lead compounds 28 and 29, which regained full in vitro potency of f152A1 and showed higher in vivo potency by iv administration.
MULTIKINASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER
-
Page/Page column 93, (2009/03/07)
The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I):...................................................................
MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS
-
Page/Page column 91-92, (2010/02/07)
The present invention provides compounds having formula (I), and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R1 -R11, t, X, Y, Z, and n are as defined herein.
